Screener
Amneal Pharmaceuticals, Inc. AMRX Affordable Medicines — Acquisition costs
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:BusinessCombinationAcquisitionRelatedCosts.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Three Months Ended June 30, 2026 | Affordable Medicines (1) | Specialty | Av KARE | Corporateand Other | Total Company |
|---|---|---|---|---|---|
| Selling, general and administrative | 42,367 | 40,095 | 16,913 | 49,347 | 148,722 |
| Research and development | 33,023 | 5,994 | — | — | 39,017 |
| Intellectual property legal development expenses | 2,002 | 85 | — | — | 2,087 |
| Acquisition costs | — | — | — | 7,600 | 7,600 |
| Restructuring and other charges | — | — | — | 554 | 554 |
| Charges related to legal matters, net | 8,057 | — | — | — | 8,057 |
| Other operating income | (1,298) | — | — | — | (1,298) |
| Operating income (loss) | $123,078 | $54,856 | $9,336 | $(57,501) | $129,769 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s affordable medicines — acquisition costs?
- Amneal Pharmaceuticals, Inc. (AMRX) reported affordable medicines — acquisition costs of $0 in Q2 2026.
- What does affordable medicines — acquisition costs mean?
- Includes the non-recurring expenses incurred during the process of acquiring and integrating new businesses or product lines into the Affordable Medicines segment. This metric helps investors isolate the impact of inorganic growth strategies on short-term financial performance.
Ask your AI about Amneal Pharmaceuticals, Inc.'s affordable medicines — acquisition costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude